|Day Low/High||0.06 / 0.06|
|52 Wk Low/High||0.04 / 3.46|
During the Lightning Round, Cramer says Dendreon is 'too speculative for this guy.'
April 9, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Monday, May 7, 2012, at 4:30 p.
These stocks look poised to break out and trade higher from current levels.
A first look at the cancer drug stocks that could run up in value as we get closer to the big ASCO conference.
Positive results from a trial of J&J's Zytiga promise to once again shift the prostate cancer drug field.
Shares of Dendreon (Nasdaq:DNDN) were gapping down Thursday morning with an open price 13.5% lower than Wednesday's closing price. The stock closed at $10.87 yesterday and opened today's trading at $9.40.
March 5, 2012--Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: Cowen and Company 32nd Annual Health Care Conference in Boston, MA, on ...
These stories made today's top 10 list of articles and videos on TheStreet.
Biotech columnist Adam Feuerstein responds to biotech stock questions posed by his Twitter followers.
February 28, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced three new appointments to the Company’s executive team.
Dendreon's CEO Discusses Q4 2011 Results - Earnings Conference Call
Dendreon (Nasdaq:DNDN) is trading at unusually high volume Monday with 35.6 million shares changing hands. It is currently at four times its average daily volume and trading down $3.02 (-20.3%).
February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2011.
February 22, 2012 – Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 27, 2012, at 9:00 a.
Alix Steel and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks on Tuesday's news.
Relative strength is one of the best tools we have to identify stocks that are likely to beat the market in 2012.
February 1, 2012 – Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 27, 2012, at 4:30 p.
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
February 1, 2012 – Dendreon Corporation (Nasdaq: DNDN) today announced that its Board of Directors has elected John H.
January 31, 2012 – Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE ® data will be presented at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium...
Medivation's MDV3100 significantly prolonged survival in prostate cancer patients and seizures -- an investor concern -- doesn't appear to be a problem.
Alix Steel and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.
Scott Redler of T3Live reviews the day's market action and sets up your trading plan for the next session.
Raising $30 million this quarter will full fund Aastrom's phase III study of its cellular therapy for patients with blocked leg arteries.
Dendreon's Management Presents at J.P. Morgan Healthcare Conference (Transcript)
TheStreet's Adam Feuerstein will give his impressions of the J.P. Morgan Healthcare Conference and answer readers' biotech investing questions.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.